erlotinib has been researched along with semaxinib in 11 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (semaxinib) | Trials (semaxinib) | Recent Studies (post-2010) (semaxinib) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 480 | 31 | 218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A; Ihnat, MA; Kurup, S; Shenoy, SS; Thorpe, JE | 1 |
| Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Zhao, Y | 1 |
| Disch, B; Gangjee, A; Ihnat, MA; Kurup, S; Thorpe, JE | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Yu, J | 1 |
| Bastian, A; Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Zaware, N | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bailey-Downs, LC; Bastian, A; Disch, BC; Dybdal-Hargreaves, NF; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL; Raghavan, S; Rohena, CC; Thorpe, JE; Zhang, X | 1 |
| Bastian, A; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL; Raghavan, S; Zammiello, C; Zhang, X | 1 |
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| Choudhary, S; Devambatla, RKV; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL | 1 |
11 other study(ies) available for erlotinib and semaxinib
| Article | Year |
|---|---|
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Diamines; Indoles; Male; Melanoma; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Pyrimidines; Pyrimidinones; Pyrroles; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; ErbB Receptors; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diamines; Enzyme Activation; ErbB Receptors; Humans; Protein Kinase Inhibitors; Pyrimidines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Design; Humans; Melanoma, Experimental; Mice; Mice, Nude; Microwaves; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Diamines; Halogenation; Humans; Indoles; Pyrimidines; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Solubility; Structure-Activity Relationship; Water | 2014 |
The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Design; ErbB Receptors; Furans; Humans; Inhibitory Concentration 50; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Neovascularization, Physiologic; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Structure-Activity Relationship; Tubulin Modulators; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
Design, synthesis and preclinical evaluation of 5-methyl-N
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |